C-Myc在多发性骨髓瘤中的研究进展  

Research progress of C-Myc in multiple myeloma

作　　者：杨宁 钟华[1] YANG Ning;ZHONG Hua(Department of Hematology,Renji Hospital,School of Medicine,Shanghai Jiao Tong University,Shanghai 200127,China)

机构地区：[1]上海交通大学医学院附属仁济医院血液科,上海200127

出　　处：《肿瘤》2021年第2期131-138,共8页Tumor

摘　　要：多发性骨髓瘤(multiple myeloma,MM)是一种浆细胞恶性增殖性疾病,其特点为克隆性浆细胞在骨髓中异常增殖,发病率在血液系统肿瘤中排第2位。C-Myc是一种原癌基因,在人类的多种实体肿瘤和血液肿瘤中异常高表达。近年来相关研究表明,C-Myc的表达增强与肿瘤的不良预后息息相关。从癌前病变单克隆丙种球蛋白病(monoclonal gammopathy of undetermined significance,MGUS)发展为冒烟型骨髓瘤(smoldering myeloma,SMM),进而发展为有症状的MM,高表达的C-Myc可能是病程进展的机制之一。因此,明确C-Myc在MM发生和发展中的作用,对于探究MM的发病机制及开发新型治疗策略具有重要指导意义。Multiple myeloma(MM)is a plasma cell malignant proliferative disease characterized by the accumulation of clonal plasma cells in bone marrow.The incidence of multiple myeloma is second in hematological malignancies.C-Myc is an oncogene that high expresses abnormally in a variety of solid tumors and hematological malignancies.It has been approved that the increased expression of C-Myc is associated with poor prognosis of tumor patients.Multiple myeloma evolves from a premalignant stage named monoclonal gammopathy of undetermined significance(MGUS),followed by smoldering MM(SMM)and finally evolved to symptomatic myeloma.C-Myc deregulation is one of the key features of disease progression.Identifying the role of C-Myc in the occurrence and development of MM is important for clarifying the pathogenesis of MM and may help in developing new treatment strategies.

关 键 词：多发性骨髓瘤 原癌基因蛋白质C-MYC 治疗 

分 类 号：R733.3[医药卫生—肿瘤]